ConverGene Announces Sponsored Research Agreement with MD Anderson CAMBRIDGE, Md., Sept. 18, 2017 (GLOBE NEWSWIRE) -- ConverGene is pleased to announce that it has entered into a collaboration with The University of Texas MD Anderson Cancer Center (“MD Anderson”)...

ConverGene Announces CRADA Agreement with The National Institute of Neurological Disorders and Stroke CAMBRIDGE, Md., April 05, 2017 (GLOBE NEWSWIRE) -- ConverGene has entered into a Collaborative Research and Development Agreement (CRADA) with the Molecular Neuropharmacology Section (MNS) of The...

ConverGene Announces Sponsored Research Agreement with University of Maryland, Baltimore to Evaluate First-in-class Anti-cancer Agents CAMBRIDGE, Md., Jan. 25, 2017 (GLOBE NEWSWIRE) -- ConverGene has entered into a Sponsored Research Agreement with University of Maryland, Baltimore. Under this agreement University of Maryland...

ConverGene Announces a License Agreement With the National Center for Advancing Translational Sciences CAMBRIDGE, Md., Dec. 13, 2016 (GLOBE NEWSWIRE) -- ConverGene has entered into an exclusive license agreement with the National Center for Advancing Translational Sciences (NCATS), part of the...